These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 23244802)

  • 1. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.
    Hornberger J; Lyman GH; Chien R; Meropol NJ
    Value Health; 2012 Dec; 15(8):1014-21. PubMed ID: 23244802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand.
    Lerdkiattikorn P; Chaikledkaew U; Lausoontornsiri W; Chindavijak S; Khuhaprema T; Tantai N; Teerawattananon Y
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):687-700. PubMed ID: 25327502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
    Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
    Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.
    Shiroiwa T; Takeuchi T; Fukuda T; Shimozuma K; Ohashi Y
    Value Health; 2012; 15(2):255-60. PubMed ID: 22433756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases.
    Ercolani G; Cucchetti A; Cescon M; Peri E; Brandi G; Del Gaudio M; Ravaioli M; Zanello M; Pinna AD
    Eur J Cancer; 2011 Oct; 47(15):2291-8. PubMed ID: 21652204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.
    Alarid-Escudero F; Schrag D; Kuntz KM
    Value Health; 2022 Mar; 25(3):409-418. PubMed ID: 35227453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany.
    Monz BU; König HH; Leidl R; Staib L; Link KH
    Pharmacoeconomics; 2003; 21(10):709-19. PubMed ID: 12828493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
    J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer.
    Alberts SR; Yu TM; Behrens RJ; Renfro LA; Srivastava G; Soori GS; Dakhil SR; Mowat RB; Kuebler JP; Kim GP; Mazurczak MA; Hornberger J
    Pharmacoeconomics; 2014 Dec; 32(12):1231-43. PubMed ID: 25154747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients.
    Brenner B; Geva R; Rothney M; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Gluzman A; Purim O; Shacham-Shmueli E; Shulman K; Mishaeli M; Man S; Soussan-Gutman L; Tezcan H; Chao C; Shani A; Liebermann N
    Value Health; 2016 Jan; 19(1):82-7. PubMed ID: 26797240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
    Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
    Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
    Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
    Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
    Yun HR; Kim HC; Yun SH; Lee WY
    Hepatogastroenterology; 2012; 59(120):2466-71. PubMed ID: 23169179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.
    Blank PR; Filipits M; Dubsky P; Gutzwiller F; Lux MP; Brase JC; Weber KE; Rudas M; Greil R; Loibl S; Szucs TD; Kronenwett R; Schwenkglenks M; Gnant M
    Pharmacoeconomics; 2015 Feb; 33(2):179-90. PubMed ID: 25404424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.
    Wu B; Li T; Cai J; Xu Y; Zhao G
    BMC Cancer; 2014 Dec; 14():984. PubMed ID: 25526802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
    Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ
    J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.